Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a strategic research collaboration agreement with Inimmune Corporation, a U.S. biotechnology firm specializing in immunotherapy and vaccine innovation. Under the terms of the agreement, Inimmune will utilize Insilico’s proprietary generative AI platform, Chemistry42, to accelerate the discovery and development of next-generation immunotherapies. Financial details of the collaboration were not disclosed.
Chemistry42 is a state-of-the-art software platform that integrates AI with computational and medicinal chemistry methods, designed to generate novel molecular structures with predefined properties. The platform has been instrumental in advancing Insilico’s drug discovery pipeline and is expected to play a significant role in the development of new immunotherapies in collaboration with Inimmune. – Flcube.com
